Introduction: Health priority setting is complex especially for decision-making to improve access and address unmet needs. Bio-Manguinhos/Fiocruz (BM) is reviewing its technology roadmap, employing a phased strategy, with in-person consultation with key opinion leaders (KOL) from the medical-scientific community. Complementarily, epidemiological data was collected, and an online survey was sent. Objectives: The main goal is to foster innovation and collaboration with research institutions and society to prioritize health demands for the next 10 years focusing on minimizing the challenges of universal access. We present the overall results of the horizon scanning process to build the 1st layer of a technology roadmap. Methodology: Workshops convening KOL were conducted in the fields of pneumology, infectious diseases, oncology, hematology, gastroenterology, dermatology, rheumatology, cardiology and neurology. Each had a scientific leader and researchers discussing major illnesses and their short, medium, and long- term needs. The guiding question was: What are the trends in diagnosis, prevention and treatment to meet current and future health needs with a focus on biotechnology? These reflections were translated into healthcare demands for further analysis. Results: From 1045 demands, 65% were in biotechnology and 35% in other areas. Of identified potential products that could be made available by BM, 43% were biotherapeutics, 35% in vitro diagnostics, 9% vaccines and 13% other supporting technologies. Regarding time horizon, 56% were long-term, 39% short term and 5% medium term, with 36% of products already available in the market and 51% innovative solutions. Concerning disease groups, by far, the highest number of biotechnological demands was required by Rheumatology (24%), whereas the lowest by Cardiology (4.6%). Conclusion: Including medical demands is a form of social participation in the decision-making process. The results found will be the basis for discussing and revising the layer related to products and technologies. This strategy, supported by other data sources, allows for a more integrated and synergistic mapping that will contribute to proposing the best immediate course of action for biotech products already.